PMID- 35429620
OWN - NLM
STAT- MEDLINE
DCOM- 20220617
LR  - 20220801
IS  - 1878-5492 (Electronic)
IS  - 0966-3274 (Linking)
VI  - 73
DP  - 2022 Aug
TI  - Loss of mismatched HLA in acute myeloid leukemia relapse after haploidentical 
      peripheral blood stem cell transplantation combined with unrelated cord blood: A 
      case report.
PG  - 101602
LID - S0966-3274(22)00076-4 [pii]
LID - 10.1016/j.trim.2022.101602 [doi]
AB  - Mismatched human leukocyte antigen (HLA) loss is an essential mechanism involved 
      in immune escape and recurrence in acute leukemia after haploidentical 
      transplantation. Patients relapsing after transplantation with HLA loss have a 
      poor prognosis, and are less likely to benefit from donor lymphocyte infusion 
      (DLI) from the original donor. Here, we report a patient with high-risk acute 
      myeloid leukemia who relapsed within six months after haploidentical peripheral 
      blood stem cell transplantation (PBSCT) combined with unrelated umbilical cord 
      blood (UCB) with a session of prophylactic DLI. This patient achieved transient 
      remission after subsequent Interferon-alpha-1b treatment for two weeks but 
      experienced a second relapse within one month. Genomic analysis by real-time PCR 
      assay revealed that this patient had a loss of an entire mismatched HLA haplotype 
      that was derived from her haploidentical donor. Haploidentical peripheral blood 
      stem cell transplantation with prophylactic DLI might be a triggering event for 
      HLA loss relapse after haploidentical transplantation combined with UCB. HLA loss 
      should be considered in patients with post-HSCT relapse, especially in 
      haploidentical transplantation.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Han, Xue
AU  - Han X
AD  - Department of Hematology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, Heilongjiang Province, 150001, China.
FAU - Zhao, Jiajia
AU  - Zhao J
AD  - Department of Hematology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, Heilongjiang Province, 150001, China.
FAU - Liu, Jie
AU  - Liu J
AD  - Department of Hematology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, Heilongjiang Province, 150001, China.
FAU - Guo, Dan
AU  - Guo D
AD  - Department of Hematology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, Heilongjiang Province, 150001, China.
FAU - Li, Huibo
AU  - Li H
AD  - Department of Hematology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, Heilongjiang Province, 150001, China. Electronic address: 
      lihuibo-1985@163.com.
FAU - Fan, Shengjin
AU  - Fan S
AD  - Department of Hematology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, Heilongjiang Province, 150001, China; NHC Key Laboratory of 
      Cell Transplantation, 23 Youzheng Street, Nangang District, Harbin, Heilongjiang 
      Province, 150001, China. Electronic address: fansj1129@sohu.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220413
PL  - Netherlands
TA  - Transpl Immunol
JT  - Transplant immunology
JID - 9309923
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Interferon-alpha)
RN  - G7407IV2FS (interferon-alfa-1b)
SB  - IM
MH  - *Cord Blood Stem Cell Transplantation/adverse effects
MH  - Female
MH  - Fetal Blood
MH  - *Graft vs Host Disease
MH  - HLA Antigens/genetics
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Histocompatibility Antigens
MH  - Histocompatibility Antigens Class I
MH  - Histocompatibility Antigens Class II
MH  - Humans
MH  - Interferon-alpha
MH  - *Leukemia, Myeloid, Acute/genetics/therapy
MH  - *Peripheral Blood Stem Cell Transplantation/adverse effects
MH  - Recurrence
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - HLA loss
OT  - Haploidentical hematopoietic blood stem cell transplantation
OT  - Relapse
OT  - Umbilical cord blood
EDAT- 2022/04/17 06:00
MHDA- 2022/06/18 06:00
CRDT- 2022/04/16 20:09
PHST- 2021/12/23 00:00 [received]
PHST- 2022/04/09 00:00 [revised]
PHST- 2022/04/10 00:00 [accepted]
PHST- 2022/04/17 06:00 [pubmed]
PHST- 2022/06/18 06:00 [medline]
PHST- 2022/04/16 20:09 [entrez]
AID - S0966-3274(22)00076-4 [pii]
AID - 10.1016/j.trim.2022.101602 [doi]
PST - ppublish
SO  - Transpl Immunol. 2022 Aug;73:101602. doi: 10.1016/j.trim.2022.101602. Epub 2022 
      Apr 13.